In the past decade, cancer immunotherapy has emerged from experimental protocols in select pathologies to a mainstay of frontline cancer therapy that has drastically improved outcomes for thousands of patients. Since the approval of the first anticancer vaccine (sipuleucel-T) in 2010, strategies for stimulating the immune system to fight cancer have evolved from monotherapy vaccination approaches adapted from infectious diseases to immune checkpoint inhibition, adoptive cell therapy, viral therapy, and many others. These clinical advances reflect pivotal discoveries in how the immune system interacts with the tumor microenvironment, leading to the identification of targetable pathways and rationally designed algorithms that account for pathology, patient, and iatrogenic factors. Despite the challenges of treating gliomas with immunotherapy, intensive efforts aimed at elucidating the underpinnings of glioma immunology and next-generation immunotherapeutic strategies have placed successful translation of the first glioma immunotherapies seemingly within reach.
Gliomas are immunologically complex tumors due to multiple, nonredundant immunosuppressive mechanisms.
[1] These include not only glioma intrinsic factors, such as expression of checkpoint molecules and secretion of immunosuppressive cytokines, [2] but also local recruitment of immunosuppressive myeloid cells [3] as well as systemic tolerance mediated by inhibition of effector function and T-cell sequestration. [4, 5] Furthermore, standard-of-care radiation and chemotherapy thwarts antitumor immune responses and prevents generation of immunologic memory in preclinical models. [6, 7] Given these obstacles, it is perhaps not surprising that initial Phase III trials of immunotherapy for glioblastoma failed to meet their primary endpoints. [8, 9] More detailed analysis of data from these and other studies, however, suggests that the immune system is capable of recognizing and eliminating gliomas. A low response rate (8%) prevented a Phase III study of nivolumab (CheckMate 143, NCT02017717) from meeting its primary endpoint of overall survival; however, survival was significantly longer for nivolumab responders than patients responding to bevacizumab (11.1 vs. 5.3 months). [10] In addition, there is indirect evidence for baseline antitumor immune activity as lymphopenia correlates with worse prognosis in glioblastoma patients. [11] Taken together, these findings, along with a large body of preclinical data, warrant redoubled efforts in developing novel, potent, and glioma-specific immunotherapeutic approaches. We envision that compiling ideas in this format will not only provide readers with a solid understanding of the state of the art in glioma immunotherapy but also afford a platform for synthesizing the ideas and insights necessary to develop groundbreaking therapeutic approaches for this devastating disease.
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